Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Patients with high-risk non-metastatic castration-resistant prostate cancer
Disadvantages in some side effects do not question advantages particularly in overall survival; hint of considerable added benefit.
Press releases
Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit
Project details
- Project no.
- A20-46
- Commission
- Commission awarded on 15.05.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed